SynopsisHepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is a major global health problem. It can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer. The global Hep.....
SynopsisHepatitis C virus (HCV) infection is detected with a blood test. The global Hepatitis C Virus Testing market was valued at US$ 1329 million in 2023 and is anticipated to reach US$ 1785.6 million by 2030, witnessing a CAGR of 4.2% during the forecast peri.....
SynopsisAttention deficit hyperactivity disorder (ADHD) is a mental health disorder that can cause above-normal levels of hyperactive and impulsive behaviors. The global Attention Deficit Hyperactivity Disorder Therapeutics market was valued at US$ 13240 million.....
SynopsisHIV tests are very accurate, but no test can detect the virus immediately after infection. How soon a test can detect HIV depends upon different factors, including the type of test being used. There are three types of HIV diagnostic tests: nucleic acid tests (.....
SynopsisResearch is now focusing on the role of physical activity, nutrition, and potential future medications that may be used to treat or prevent sarcopenia. The global Sarcopenia Healthcare market was valued at US$ 2762.8 million in 2023 and is anticipated to.....
SynopsisThe FDA defines remote clinical trials as those executed through telemedicine and mobile/local healthcare providers, using processes and technologies that differ from the traditional clinical trial model. The global Remote Clinical Trials market was valu.....
Synopsis Wellness describes itself as complete physical mental and social well-being. The global Healthcare and Wellness market was valued at US$ 5243 million in 2023 and is anticipated to reach US$ 8419.1 million by 2030, witnessing a CAGR of .....
SynopsisEYLEA® (aflibercept) Injection 2 mg (0.05mL) is a prescription medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (AMD). The global Eylea market was valued at US$ 5617 million in 2023 and is anticipated to reach US$.....
SynopsisAflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. The global Aflibercept Drug market was valued at US$ 5617 million in 2023 and is anticipated to reach US$ .....
SynopsisArcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis. The global Arcalys.....
